



Nebraska Medicaid
Pharmaceutical and Therapeutics Committee Agenda
Wednesday, October 28th, 2026

Mahoney State Park, Peter Kiewit Lodge
28500 West Park Hwy, Ashland, NE 68003

*A State Park Permit is required

*A daily parking permit fee of \$7 (NE licensed vehicles) or \$14 (non-NE licensed vehicles) can be purchased at the gate or front desk.

*Please note meeting will be in-person only. There will not be a virtual attendance option.

08:00 a.m. Registration

09:00 a.m. Opening of Public Meeting and Call to Order

***All Times Below are
Approximated**

Roll Call

Committee Business

- Conflict of Interest Updates
- Approval of Meeting Minutes: May 13th, 2026
- Department Information
- Introduction of New P&T Members
- Update Proposal to Bylaws (Article VI-Quorum and Voting)

09:15 – 10:15 a.m. Public Testimony (for Products Recommended to be Non-Preferred)

- https://nebraska.fhsc.com/Downloads/NE_PT_PublicTestimony_Guidelines.pdf
- <http://dhhs.ne.gov/Pages/Pharmacy-Drug-Testimony.aspx>
- Public Testimony Registration Applications will only be accepted by online registration – No faxed/mailed requests will be accepted

10:15 – 11:15 a.m. Committee Closed Session – Session to Public Attendees Will Close

11:15 – 12:00 p.m. Resume Open Session, Room Re-opens for Public Attendees

- Consideration of Consent Agenda
- Consideration of Therapeutic Class Reviews

12:00 – 1:00 p.m. Working Lunch for Committee Members – Closed Session

1:00 – 5:00 p.m. Resume Open Session
Consideration of Therapeutic Class Reviews (Continued)
Break (if required)
Adjournment

Next meeting: Wednesday, May 12th, 2027

Consent Agenda: (Therapeutic Categories with Unchanged Recommendations)

The following classes have no changes recommended by the Department and will all be voted on as a group, unless a class is removed from the Consent Agenda.

ANTHELMINTICS	LEUKOTRIENE MODIFIERS
ANTI-ALLERGENS, ORAL	LEUKOTRIENE MODIFIERS
ANTIHYPERTENSIVES	METHOTREXATE
ANTIPSORIATICS, ORAL	MOVEMENT DISORDERS
ANTIPSORIATICS, TOPICAL	ONCOLOGY, ORAL - PROSTATE
ANXIOLYTICS	ONCOLOGY, ORAL - SKIN
BRONCHODILATORS, BETA AGONIST	OPHTHALMIC ANTIBIOTIC-STEROID COMBINATIONS
COUGH AND COLD, NARCOTIC	OTIC ANTI-INFECTIVES & ANESTHETICS
ENZYME REPLACEMENT, GAUCHERS DISEASE	SEDATIVE HYPNOTICS
EPINEPHRINE, SELF-ADMINISTERED	SICKLE CELL ANEMIA TREATMENTS
ERYTHROPOIESIS STIMULATING PROTEINS	STERIODS, TOPICAL HIGH
HISTAMINE II RECEPTOR BLOCKER	STERIODS, TOPICAL LOW
IMMUNOMODULATORS, TOPICAL	STERIODS, TOPICAL MEDIUM

Therapeutic Class Reviews: (Therapeutic Categories with New Recommendations)

ALZHEIMER'S AGENTS	ONCOLOGY, ORAL - BREAST
ANTIHISTAMINES, MINIMALLY SEDATING	ONCOLOGY, ORAL - HEMATOLOGIC
ANTIHYPERTENSIVES, SYMPATHOLYTICS	ONCOLOGY, ORAL - LUNG
ANTIPARKINSON'S AGENTS	ONCOLOGY, ORAL - OTHER
BILE SALTS	ONCOLOGY, ORAL - RENAL CELL
COLONY STIMULATING FACTORS	OPHTHALMIC ANTIBIOTICS
COPD AGENTS	OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS
CYTOKINE AND CAM ANTAGONISTS	OPHTHALMICS, ANTI-INFLAMMATORIES
GLUCOCORTICOIDS, INHALED	OPHTHALMICS, DRY EYE AGENTS
GLUCOCORTICOIDS, ORAL	OPHTHALMICS, GLAUCOMA AGENTS
HEMOPHILIA TREATMENT	OTIC ANTIBIOTICS
IDIOPATHIC PULMONARY FIBROSIS	STERIODS, VERY HIGH
IMMUNOMODULATORS, ASTHMA	STIMULANTS AND RELATED AGENTS
IMMUNOMODULATORS, ATOPIC DERMATITIS	THROMBOPOIESIS STIMULATING PROTEINS
NSAIDS	